NCT06446050View on ClinicalTrials.gov

Chemokine and Co-stimulatory Molecule-modified Mesenchymal Stem Cells for the Treatment of Advanced Colorectal Cancer

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 21, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Advanced Colorectal Cancer
Interventions
BIOLOGICAL

MSC-L

Human umbilical cord-derived mesenchymal stem cells (MSCs) genetically modified to express antitumor chemokine and co-stimulatory molecule will be administered intravenously at a dose of 1/2/3 x 10\^6 cells/kg, every 21 days for at least 6 cycles of treatment.

Trial Locations (1)

200123

RECRUITING

Shanghai East Hospital (South Division), Shanghai

All Listed Sponsors
lead

Shanghai East Hospital

OTHER